Evolution of synchronous female bilateral breast cancers and response to treatment
-
Published:2023-03
Issue:3
Volume:29
Page:646-655
-
ISSN:1078-8956
-
Container-title:Nature Medicine
-
language:en
-
Short-container-title:Nat Med
Author:
Hamy Anne-SophieORCID, Abécassis Judith, Driouch Keltouma, Darrigues Lauren, Vandenbogaert Mathias, Laurent Cecile, Zaccarini FrancoisORCID, Sadacca Benjamin, Delomenie Myriam, Laas Enora, Mariani Odette, Lam Thanh, Grandal Beatriz, Laé Marick, Bieche Ivan, Vacher SophieORCID, Pierga Jean-Yves, Brain Etienne, Vallot Celine, Hotton Judicael, Richer Wilfrid, Rocha Dario, Tariq Zakia, Becette Veronique, Meseure DidierORCID, Lesage LaetitiaORCID, Vincent-Salomon AnneORCID, Filmann Natalie, Furlanetto Jenny, Loibl Sibylle, Dumas Elise, Waterfall Joshua J.ORCID, Reyal FabienORCID
Abstract
AbstractSynchronous bilateral breast cancer (sBBC) occurs after both breasts have been affected by the same germline genetics and environmental exposures. Little evidence exists regarding immune infiltration and response to treatment in sBBCs. Here we show that the impact of the subtype of breast cancer on levels of tumor infiltrating lymphocytes (TILs, n = 277) and on pathologic complete response (pCR) rates (n = 140) differed according to the concordant or discordant subtype of breast cancer of the contralateral tumor: luminal breast tumors with a discordant contralateral tumor had higher TIL levels and higher pCR rates than those with a concordant contralateral tumor. Tumor sequencing revealed that left and right tumors (n = 20) were independent regarding somatic mutations, copy number alterations and clonal phylogeny, whereas primary tumor and residual disease were closely related both from the somatic mutation and from the transcriptomic point of view. Our study indicates that tumor-intrinsic characteristics may have a role in the association of tumor immunity and pCR and demonstrates that the characteristics of the contralateral tumor are also associated with immune infiltration and response to treatment.
Publisher
Springer Science and Business Media LLC
Subject
General Biochemistry, Genetics and Molecular Biology,General Medicine
Reference65 articles.
1. Chen, Y., Thompson, W., Semenciw, R. & Mao, Y. Epidemiology of contralateral breast cancer. Cancer Epidemiol. Biomarkers Prev. 8, 855–861 (1999). 2. Hartman, M. et al. Incidence and prognosis of synchronous and metachronous bilateral breast cancer. J. Clin. Oncol. 25, 4210–4216 (2007). 3. Vuoto, H. D. et al. Bilateral breast carcinoma: clinical characteristics and its impact on survival. Breast J. 16, 625–632 (2010). 4. Sakai, T. et al. National trends of synchronous bilateral breast cancer incidence in the United States. Breast Cancer Res. Treat. 178, 161–167 (2019). 5. Carmichael, A. R., Bendall, S., Lockerbie, L., Prescott, R. & Bates, T. The long-term outcome of synchronous bilateral breast cancer is worse than metachronous or unilateral tumours. Eur. J. Surg. Oncol. 28, 388–391 (2002).
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|